title: Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
abstract: The capacity of alpha-interferon (alpha-IFN) to induce lymphokine activated killer (LAK) cytotoxicity in the absence of interleukin-2 (IL2) has prompted us to test whether its ability to reduce dramatically the number of Ph1+ clones in chronic myelogenous leukemia (CML) patients is in part mediated through the generation of natural killer (NK) or LAK activity. The latter were tested using NK-sensitive (K562) and NK-resistant (Raji) cell lines in a target-cell colony-growth inhibition assay. Effector cells (E) were patient blood mononuclear cells (MC) without in vitro activation prior to their coculture with targets (T). Here we report that cytogenetic remission in alpha-IFN-treated patients is associated with significantly enhanced NK and LAK activities. Nevertheless, some patients under alpha-IFN therapy were found to develop lymphoid blast crisis despite high levels of NK and LAK activities, and partial or total cytogenetic remission. In contrast, most of the patients who developed nonlymphoid blast crisis presented 100% Ph1+ cells and displayed defective NK and/or LAK activity. These observations could favor the hypothesis that there is an indirect but complex effect of alpha-IFN on leukemic cells, mediated by cells involved in immune surveillance; and also that lymphoid blast cells may actually escape LAK cytotoxicity.
authors.affiliation: URA CNRS 1172, IBMIG, Poitiers, France.
authors.forename: A
authors.initials: A
authors.lastname: Meseri-Delwail
authors.forename: V
authors.initials: V
authors.lastname: Delwail
authors.forename: A
authors.initials: A
authors.lastname: Brizard
authors.forename: P
authors.initials: P
authors.lastname: Goube de Laforest
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: J C
authors.initials: JC
authors.lastname: Lecron
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D002460:Cell Line; D002648:Child; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects*; D007694:Killer Cells, Natural / Q000187:drug effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology*; D008213:Lymphocyte Activation; D008285:Major Histocompatibility Complex / Q000187:drug effects; D008297:Male; D008875:Middle Aged
chemical_list: D016898:Interferon-alpha